Actively Recruiting

Phase 4
Age: 18Years - 100Years
All Genders
NCT05675527

PRP for Glenohumeral Osteoarthritis

Led by Hospital for Special Surgery, New York · Updated on 2025-10-06

135

Participants Needed

1

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

CONDITIONS

Official Title

PRP for Glenohumeral Osteoarthritis

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 100 years
  • Average pain score of 5 or higher out of 10 due to glenohumeral osteoarthritis or cartilage damage
  • Shoulder pain lasting at least 3 months after symptom onset that has not improved with conservative treatments, including physical therapy
  • MRI of the affected shoulder joint
  • Temporary relief of symptoms after a diagnostic intra-articular injection into the shoulder joint
  • Access to email or internet network
Not Eligible

You will not qualify if you...

  • Unable to avoid non-steroidal anti-inflammatory drugs for 2 weeks before and 1 month after the injection
  • Previous platelet-rich plasma injection in the affected joint
  • Steroid injection in the affected joint within 3 months before the injection
  • Hyaluronic acid injection in the affected joint within 6 months before the injection
  • Involved in workers' compensation or active legal cases related to the affected shoulder
  • History of using Plavix medication
  • Known uncontrolled systemic illnesses such as uncontrolled diabetes, HIV, vasculitis, or autoimmune/autoinflammatory diseases
  • Presence of recent fractures or major mechanical deformities in the shoulder
  • Uncontrolled cervical spine disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hospital for Special Surgery

New York, New York, United States, 10021

Actively Recruiting

Loading map...

Research Team

J

Jonathan Kirschner, MD

CONTACT

J

Jennifer Cheng

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here